PRSYM Highlights 2026
ARP Member: $325.00
ARP Non-Member: $650.00
Student/Resident/Transitional Member: $325.00
Activity Overview
The Pediatric Rheumatology Symposium (PRSYM) Highlights will provide up-to-date, practical clinical information and basic science knowledge on the diagnosis and management of pediatric patients with rheumatic diseases and immune disorders.
Topics
Addressing Key Issues in Pediatric Rheumatology
- My Life as a History Lesson and a Call to Action
Courtney Wells, PhD, MPH, MSW - A Different World—Viewing Pediatric Rheumatology through a Global Lens
Laura Lewandowski, MD, MSc - Minding the Gap: Understanding and Addressing Representativeness and Disparities in Pediatric Rheumatology Research
Jennifer Woo, PhD, MPH - General Pediatric and Subspecialty Workforce Challenges and Potential Solutions
Speaker: Colleen Correll, MD, MPH - Panel Discussion
Courtney Wells, PhD, MPH, MSW; Laura Lewandowski, MD, MSc; Jennifer Woo, PhD, MPH; Colleen Correll, MD, MPH
Clinical Management
- Harnessing AI
Bella Mehta, MD - From Promise to Practice: The Evolving Biosimilar Landscape in Pediatric Rheumatology
Ingrid Pan, PharmD - What Do We Know About Vaccinations in Kids with Inflammatory Rheumatic Diseases?
Merav Heshin-Bekenstein, MD
Systemic Lupus Erythematosus
- Pediatric Antiphospholipid Syndrome: A Few Bad aPLs
Jacqueline Madison, MD - Hitting the Target: Optimizing Outcomes in Childhood Lupus
Eve Smith, MD, PhD, BSc - Multitarget Therapy is Necessary for the Treatment of cSLE: A Great Debate
Hermine Brunner, MD, MSc, MBA, FAAP, FACR; and Aimee Hersh, MD, MS
Juvenile Idiopathic Arthritis
- Not So Silent After All—Demystifying the Temporomandibular Joint
Marinka Twilt, MD, PhD, MSc - From Clues to Clarity: Axial Disease in Juvenile Spondyloarthritis
Pam Weiss, MD - Imaging as a Biomarker: Peripheral Joint Insights in JIA
Patricia Vega-Fernandez, MD, RhMSUS, MSc - Panel Discussion
Pam Weiss, MD; Marinka Twilt, MD, PhD, MSc; Patricia Vega-Fernandez, MD, RhMSUS, MSc
Clinical Update - Guidlines & Recommendations
- Uveitis: Clinical Trials & PROs
Sheila Angeles Han, MD, MSc - Mental Health Guidance Statements
Tamar Rubinstein, MD, MS
Juvenile Dermatomyositis and Scleroderma
- Let’s Strengthen our Research in JDM: How to Perform and Collect Critical Measures in Clinical Practice
Kaveh Ardalan, MD, MS; Stacey Tarvin, MD, MS, FACR; Amy Rakestraw, PT, MPH - Guidance for Stem Cell Therapy for Juvenile Systemic Sclerosis Patients
Kathryn Torok, MD
Vasculitis
- Advancing Pediatric ANCA-Associated Vasculitis: Insights from Collaborative Research and Emerging Clinical Data
Jessica Bloom, MD, MS - Renal Disease and Risk Stratification in Pediatric ANCA-associated Vasculitis (AAV)—Insights from the Pediatric Vasculitis Initiative
Kelly Brown, PhD
QI/Implementation
- How to Integrate Data Elements into Clinical Care and Decision Making
Danielle Bullock, MD, MPH - Transition Readiness
Melissa Argraves, MD, MEd - PR-COIN: Improving JIA Outcomes
Julia Harris, MD - Mental Health Screening
Mileka Gilbert, MD, PhD - Panel Discussion
Danielle Bullock, MD, MPH; Melissa Argraves, MD, MEd; Julia Harris, MD; Mileka Gilbert, MD, PhD
Systemic Juvenile Idiopathic Arthritis
- Still's Disease—EULAR/PReS Recommendations
Fabrizio De Benedetti, MD, PhD - IL-18 Inflammosopathy
Scott Canna, MD - CAR-T Therapy: European Experience
Fabrizio De Benedetti, MD, PhD - Situational Awareness for New Passengers in the CAR(-T)
Christen Ebens, MD, MPH
Target Audience
Rheumatologists, rheumatology interprofessionals, fellows in training, and residents.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the most up-to-date clinical information on the diagnosis and management of pediatric patients with rheumatic and immunologic disorders
- Describe the most current information regarding the pathophysiology underlying pediatric rheumatic disorders
CE & MOC Information
In support of improving patient care, the American College of Rheumatology (ACR) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
See the ACR’s CE Mission Statement. For more information, download the AMA PRA Booklet.
Available Credit
- AMA PRA Category 1 Credit(s)™: 13.00
- ABIM MOC: 13.00
- ABP MOC: 13.00
ACCME Designation Statement
The American College of Rheumatology designates this enduring material for a maximum of 13.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.MOC
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for diplomates to the diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the Physician Portals. Please allow at least 48 hours for points to display in the portal.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
MOC Recognition Statement: American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 13.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patent beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. PRSYM Highlights 2026 Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.